Breaking News, Collaborations & Alliances

Arcturus, Catalent Partner to Manufacture COVID-19 Vaccine

The manufacture of LUNAR-COV19 at Catalent’s drug substance biomanufacturing facility in Madison, WI will support human clinical studies

By: Contract Pharma

Contract Pharma Staff

Arcturus Therapeutics, a clinical-stage messenger RNA (mRNA) medicines and vaccines company, and Catalent, a global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, have formed a partnership to support the expected manufacture of Arcturus’ COVID-19 mRNA vaccine candidate (LUNAR-COV19), intended to protect against the SARS-CoV-2 coronavirus.   LUNAR-COV19 utilizes Arcturus’ self-transc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters